cbdMD (YCBD) Income towards Parent Company (2016 - 2025)
cbdMD (YCBD) reported Income towards Parent Company of -$283131.0 for Q4 2025, down 1975.66% on a YoY basis from $15095.0 in Q4 2024, and up 58.36% sequentially from -$679968.0 in Q3 2025.
cbdMD (YCBD) Income towards Parent Company (2016 - 2025) Analysis & Trends
cbdMD (YCBD) has 10 years of Income towards Parent Company data on file, last reported at -$283131.0 in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company fell 1975.66% year-over-year to -$283131.0; the trailing twelve-month figure through Dec 2025 stood at -$2.3 million (up 13.0% YoY), and the FY2025 full-year result was -$2.0 million, up 44.84% from the prior year.
- Income towards Parent Company rose to -$283131.0 in Q4 2025, from -$679968.0 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $459737.0 in Q2 2024 to a low of -$31.6 million in Q2 2022.
- A 5-year average of -$5.8 million and a median of -$1.3 million in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company soared 125.97% in 2024 and slumped 1975.66% in 2025, its largest moves.
- Tracing YCBD's Income towards Parent Company over 5 years: stood at -$19.2 million in 2021, then surged by 79.35% to -$4.0 million in 2022, then surged by 74.81% to -$996501.0 in 2023, then soared by 101.51% to $15095.0 in 2024, then tumbled by 1975.66% to -$283131.0 in 2025.
- Business Quant data shows YCBD's Income towards Parent Company at -$283131.0 in Q4 2025, -$679968.0 in Q3 2025, and -$895272.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | cbdMD | 4.82 Mn | 1.43 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -283,131.00 |
| Sep 30, 2025 | -679,968.00 |
| Jun 30, 2025 | -895,272.00 |
| Mar 31, 2025 | -480,757.00 |
| Dec 31, 2024 | 15,095.00 |
| Sep 30, 2024 | -152,799.00 |
| Jun 30, 2024 | 459,737.00 |
| Mar 31, 2024 | -3.01 Mn |
| Dec 31, 2023 | -996,501.00 |
| Sep 30, 2023 | -15.87 Mn |
| Jun 30, 2023 | -1.77 Mn |
| Mar 31, 2023 | -1.34 Mn |
| Dec 31, 2022 | -3.96 Mn |
| Sep 30, 2022 | -14.63 Mn |
| Jun 30, 2022 | -31.63 Mn |
| Mar 31, 2022 | -4.66 Mn |
| Dec 31, 2021 | -19.16 Mn |
| Jun 30, 2020 | -7,781.00 |
| Dec 31, 2019 | -41,202.00 |
| Sep 30, 2019 | -2.46 Mn |